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Abstract
The pathogenesis of systemic sclerosis (SSc) is complex and
largely unclear. The clinical heterogeneity of the disease and its
progression over a number of years makes the choice of end-
points in the design of clinical trials difficult. The overwhelming
need in this disease is to diagnose it early and identify those
patients who will benefit most from early, aggressive treatment
that potentially can alter the clinical disease course. To achieve
this, innumerable challenges must be overcome. This article
reviews data from recent clinical trials and the lessons derived
from retrospective observational studies, databases, and patient
registries. Taken together, these observations will help to
improve our understanding of the diverse clinical course of SSc
and permit refinement of existing outcome measures for the
design of future clinical trials, in which the likelihood of observing
a positive treatment effect with the drugs at our disposal will be
maximized.
Introduction
As is comprehensively reported in the previous reviews in this
supplement, systemic sclerosis (SSc) is a multisystem
disorder with a complex pathogenesis that remains to be
elucidated. It is apparent that a combination of environmental
or genetic factors leads to early immune activation and even
earlier vascular damage, which leads ultimately, through a
variety of signals, to myofibroblast differentiation and prolifer-
ation. The net result of these perturbations is profound
vascular damage and tissue injury, characterized by fibrosis
and remodelling. This review examines data from clinical trials
as well as those from observational databases and registries.
The aim is to present information gleaned from recent clinical
experience of current therapeutic approaches and to highlight
the many challenges to the SSc community that still remain to
be overcome.
Lessons from clinical trials in systemic
sclerosis
Disease modification in SSc means extension of lifespan.
With this in mind, several drugs are now available to manage
the specific manifestations of scleroderma, including angio-
tensin-converting enzyme inhibitors for renal crisis [1] and
epoprostenol for pulmonary arterial hypertension (PAH) [2].
Available data for the dual endothelin receptor antagonist
bosentan suggest that it may also be considered a life-pro-
longing agent in the setting of PAH-SSc [3], and it is hoped
that cyclophosphamide will be as effective in pulmonary
fibrosis (PF) [4]. However, although significant advances are
being made, these are mainly with respect to specific organ
involvement. In the following sections some of these recent
clinical trial data are reviewed to show how they are contribu-
ting to our understanding of therapeutic approaches that may
be appropriate in the management of SSc. We also highlight
key observations that have been reported and are helping to
shape the future of clinical trials.
Nonspecific antifibrotic agents
D-penicillamine and relaxin
The anticollagen and immune-modulating effects of D-
penicillamine provided a rationale for testing its efficacy in
diffuse cutaneous SSc, specifically to slow skin fibrosis.
However, although some observational studies initially
appeared to demonstrate improved skin thickening,
significant benefit in 5-year mortality and a decrease in
development of visceral disease, these benefits were not
confirmed in a well controlled, randomized, double-blind trial
[5]. This trial enrolled 134 patients who were approximately
10 months into their disease and had a mean skin score of
about 20. After 24 months, no significant differences in skin
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scores were observed between patients receiving low doses
of D-penicillamine (125 mg every other day) and those
receiving usual doses (750 to 1,000 mg/day).
Relaxin is an antifibrotic pregnancy-related hormone that is
responsible for loosening the pelvic ligaments to facilitate
parturition [6]. At the transcriptional level, relaxin reduces the
production of collagen types I and III, enhances collagenase
types I and III, and reduces the level of tissue inhibitor of
matrix metalloproteinase. Thus, relaxin has three putative
antifibrotic mechanisms. A phase II study comparing relaxin
with placebo in patients with diffuse SSc in later stages
yielded promising results [7]. In the 25 µg patient cohort, a
statistically significant reduction in skin score from 27 to 19
by week 24 was observed. Disappointingly, these results
were not repeated in a subsequent phase III study involving
231 patients, despite entry skin scores and other
characteristics being identical to those in the phase II study
(Seibold JR, unpublished data). This study, which compared
the effective dose from the phase II study (25 µg) with a
10 µg dose and placebo, detected identical responses for the
25 µg dose and placebo.
Methotrexate
Two randomized, double-blind, placebo-controlled trials
evaluated the antifolate drug methotrexate in patients with
SSc [8,9]. In the first of these trials, 29 SSc patients (37.9%
with diffuse disease; mean disease duration about 3 years)
were randomly assigned to receive methotrexate 15 mg/week
for 24 weeks [8]. After the initial 24-week double-blind
period, patients who responded favourably (improvement in
total skin score, visual–analogue scale improvement of
≥30%, or improvement in carbon dioxide diffusing capacity
[DLCO] of ≥15%) continued for a further 24 weeks on the
same treatment in an observational extension phase. Those
who responded poorly on placebo were given methotrexate
15 mg/week and those who responded poorly on metho-
trexate had their dose increased to 25 mg/week. Although
the patient numbers were small, significantly more patients on
methotrexate responded favourably compared with the
placebo group (P = 0.03). However, improvement in individual
measures only tended toward significance. Of the 22 patients
who received methotrexate for at least 24 weeks, and
completed the trial, 68% responded to methotrexate therapy.
A more recent randomized, double-blind trial was conducted
in 71 early diffuse SSc patients (duration < 3 years; mean
duration < 7.5 months), who were randomly assigned to
receive either methotrexate (n = 35) titrated up to 15 mg/week
or placebo (n = 36) for 12 months [9]. Baseline skin scores
were similar in the two groups; the mean University of
California, Los Angeles (UCLA) score was about 11 and the
modified Rodnan skin score (mRss) was about 27. Although
the study concluded that there was little evidence that
methotrexate is significantly effective in the treatment of early
diffuse SSc, there were some significant differences between
patients given methotrexate and those who received placebo.
In patients who completed the trial (n = 54), UCLA skin
scores were significantly better in the methotrexate group
than in the placebo group after 3 months (P < 0.05), although
this difference was not maintained at 12 months. The mRss
improved over the course of the study, and although
differences compared with placebo never reached formal
significance, such a trend was present and was supported by
the UCLA score. At 12 months, despite the lack of quanti-
tative differences in skin scores and other parameters, such
as patient global assessment, Health Assessment Question-
naire (HAQ) pain and disability, and grip strength, the
physician global assessment was significantly better for
patients given methotrexate (P < 0.035). Overall, this study
supported the initial study of van den Hoogen and coworkers
[8], although it was far from a ringing endorsement.
Summary
Some patients appear to benefit from methotrexate, although
a substantial proportion fails to respond to therapy. The
disappointing results with both D-penicillamine and relaxin
may be because these agents are not well suited to SSc
pathophysiology as both can be considered nonspecific
antifibrotic agents. However, a valuable lesson from these
trials was the finding of a quantifiable, spontaneous
improvement in some patients with SSc.
Targeting the systemic sclerosis-specific
pathophysiology
The largely disappointing results from the trials of nonspecific
antifibrotic agents prompted an evaluation of cumulative data
on ineffective drugs and placebo arms of trials, which was
performed by a core panel of trained experts [10]. Forced
vital capacity (FVC), mRss, and HAQ findings from 645
patients with early diffuse SSc were evaluated to gain
information on disease progression in these patients. The
results indicated that although patients entered the studies
with an mRSS in the region of 27, this reduced to about 13
at the 24-month point, representing a 50% spontaneous
reduction over 2 years. Interestingly, patients who entered
trials with relatively mild disease at the outset tended to
worsen, and those that entered with relatively severe disease
tended to exhibit spontaneous improvement. This demon-
strates significant regression to the mean, and indicates that
establishment of stable baseline data and good training are
necessary to decrease variability of measurements so that
realistic targets for analysis can be set.
The observations of spontaneous improvement of skin in
patients with diffuse SSc led to the investigation of disease
progression in the lung. In contrast to idiopathic pulmonary
fibrosis, an aggressive and rapidly progressive condition,
interstitial lung disease (ILD) secondary to SSc (SSc-ILD)
progresses more slowly and is well recognized for its stability
after an initial 1-year or 2-year period of decline [11]. The
cumulative analysis of the clinical trial data [10] showed that
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patients with early diffuse SSc entered and left the trials with
%FVC values in the high 70s. Thus, ILD tends to accrue
early but is more stable in later stages. It may therefore be
that it is not progressive interstitial fibrosis but rather
progressive vascular injury in the lung that leads to a
diminishing diffusing capacity over time. Surprisingly,
however, diffusing capacity (%DLCO) at entry was in the low
60s and tended to remain stable.
Some positive results with methotrexate have been observed
in relatively small numbers of SSc patients. However, the
combined findings of these trials and of the evaluation of
ineffective nonspecific therapies and placebo data suggest
that a more specific approach, through targeting pertur-
bations that are typical of SSc, may be more appropriate and
may yield more promising results.
CAT-192
As presented in other reviews in this supplement [12,13],
transforming growth factor-β appears to be an important
mediator of much of the pathophysiology of SSc, particularly
in terms of extracellular matrix deposition and vasculature
injury. A recent study of CAT-192, which is a fully humanized,
monoclonal antibody to transforming growth factor-β1,
examined change in mRss over 6 months in patients with
diffuse, progressive SSc in its earliest possible stage, who
had a median disease duration at baseline of just 6.4 months
[14]. Disappointingly, there was no good evidence to suggest
that the drug had any effect on mRss, but this findings could
have been a reflection of regression toward the mean or the
very small number of patients in each group (n = 7 to 9), or it
could have been due to the lack of robust metrics available to
measure the natural history of the disease. The lesson from
this study is that adequate power is critical, even in early
phase I studies, if treatment effects are to be demonstrated in
subsequent studies.
Bosentan: BUILD-2 trial
Pulmonary complications, including interstitial fibrosis and
pulmonary vasculopathy, are now the leading causes of death
in patients with SSc. There is considerable evidence to
suggest that endothelin (ET)-1 is a key participant in many of
the pathological features of SSc. Plasma levels are elevated
in SSc patients, particularly those with PAH or ILD, and ET-1
is over-expressed in as-yet-uninvolved and early-involved skin
[15]. Furthermore, SSc lung fibrosis is associated with
elevated ET-1 ligand expression and increased expression of
endothelin receptor subtype B binding sites. Bosentan, a
dual endothelin receptor antagonist, has been shown to
improve exercise capacity, haemodynamic parameters, time
to clinical worsening and quality of life in patients with PAH
related to connective tissue disease, including SSc [16-18].
The BUILD-2 (Bosentan in Interstitial Lung Disease in
Systemic Sclerosis-2) trial [19] compared the effects of
bosentan with those of placebo on clinical outcomes of
patients with SSc with ILD. It was designed to select patients
with progressive disease. The primary outcome measure was
6-minute walk distance (6MWD) at 12 months; secondary
measures included dyspnoea indices, pulmonary function and
other SSc features (including mRss and scleroderma HAQ),
and quality of life (QoL).
The study found no differences in effect on 6MWD and no
effect on key secondary outcomes, including FVC and DLCO,
and time to desaturation (Figure 1) [19]. This might have
been due to the 6MWD not being appropriate for assessing
treatment effects in parenchymal lung disease or to the fact
that, despite efforts to select a population with progressive
disease, the patients enrolled in the study had relatively
stable disease. Progression of SSc is characterized by periods
of spontaneous improvement in skin scores and stabilization
of pulmonary function tests, which confounds the selection of
patients with progressive disease. Although this trial did not
succeed in demonstrating that bosentan improved or
stabilized SSc-ILD, it did initiate debate on validation of the
6MWD test in SSc and suggested that there is a need for
measures that are sufficiently sensitive to changes
throughout the duration of the study [20].
Bosentan: RAPIDS-1 and RAPIDS-2 (bosentan in digital
ulcers)
Given the potentially critical role of ET-1 in the patho-
physiology of SSc, additional areas of interest are other
vascular manifestions of the disease. Digital ulcers (DUs) are
a major cause of morbidity in SSc patients, with at least 50%
of patients experiencing DUs at some point in their disease
course. DUs represent a significant burden of the disease.
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Figure 1
Key outcomes for the BUILD-2 study of bosentan versus placebo in
SSc-ILD. BUILD, Bosentan in Interstitial Lung Disease in Systemic
Sclerosis; DLCO, carbon dioxide diffusing capacity; EOS, end of study;
FVC, forced vital capacity; ILD, interstitial lung disease; 6MWD, 6 min
walk distance; Rx, treatment; SSc, systemic sclerosis.
They are excruciating, unsightly and frequently become
infected. Those that become gangrenous or a nidus of
deeper infection frequently autoamputate or require formal
surgical amputation.
RAPIDS-1 (RAndomized Placebo-controlled Investigation of
Digital ulcers in Scleroderma) demonstrated that bosentan
could reduce the number of new DUs [21]. In this
randomized, prospective, placebo-controlled, double-blind
study, 122 patients with a history of a documented DU within
the previous 12 months were randomly assigned to drug
(bosentan 125 mg twice daily) or placebo. After 12 weeks,
although bosentan therapy had no effect on the healing of
existing DUs, the mean number of new DUs during this
period was 2.7 in patients given placebo and 1.4 in those
who received bosentan, representing a reduction of 48%.
The lack of a reported effect on healing might have been
partly due to difficulties in the precise identification and
measurement of DUs. Photographing DUs is not a viable
approach because of technical issues, and no fully validated
measurement for DUs has yet been developed.
A further trial, RAPIDS-2 [22], built upon the findings of
RAPIDS-1 and examined the effects of bosentan treatment
on a designated cardinal ulcer. The results were in agreement
with those from the RAPIDS-1 study, and the consistency of
findings between these two large, placebo-controlled trials
supports the use of bosentan to reduce the number of new
DUs in SSc and a role for endothelin in maintaining vascular
integrity and function. However, bosentan was not associated
with improved healing of existing active ulcers.
An important lesson from these studies is that validated
measurement techniques must be defined and clinical trials
sufficiently powered if they are to detect differences in
outcome in SSc.
Cyclophosphamide in interstitial lung disease
A double-blind, randomized, placebo-controlled trial of the
oral immunosuppressant cyclophosphamide was conducted
in 158 patients with SSc with evidence of ILD by high-
resolution computed tomography or bronchoalveolar lavage
[4]. The enrolled patients received treatment with the oral
immunosuppressant cyclophosphamide (1.5 to 2 mg/kg per
day) or matching placebo for 1 year, and were followed for an
additional year. Of 158 patients, 145 completed at least
6 months of treatment and were included in the analysis. The
%FVC predicted stabilized or improved in patients on
cyclophosphamide and worsened in patients on placebo.
There was a mean absolute difference in adjusted 12-month
%FVC predicted between the cyclophosphamide and
placebo groups of 2.53%, favouring cyclophosphamide
(P < 0.03; Figure 2). When this effect was adjusted for the
level of fibrosis, the effect increased to approximately 2.9%. A
year of cyclophosphamide therapy for a 3% change in FVC
is, at face value, somewhat difficult to accept. Nevertheless,
there was evidence of benefit in this trial, particularly in
patients with more severe disease. This confounds the
prevention paradigm in ILD, but it makes an argument that
some of this effect may be driven by severity. A change of 1
point in the transitional dyspnoea index focal score is
considered clinically meaningful [23], and there was a
significant improvement in the cyclophosphamide group
compared with placebo (+1.4 versus -1.3; P < 0.001).
Changes favouring cyclophosphamide were also seen for
skin score, the scleroderma HAQ, the Transitional Dyspnoea
Index and components of the 36-item Short Form, which
indicates that individuals with SSc and ILD benefited in more
than one way from cyclophosphamide therapy. Further
analysis will be needed to determine whether this study can
be instructive regarding which patients are most likely to
benefit from treatment. Neither bronchoalveolar lavage nor
unvalidated, semiquantitative scoring of high resolution
computed tomography data were predictive of clinical course
or response to therapy.
It appears that careful patient selection, adequate numbers,
good quality assurance and sophisticated analysis are all
necessary when testing modestly effective drugs in SSc.
Autologous stem cell therapy
An open-label pilot study of immunoablation followed by stem
cell replacement demonstrated dramatic improvements in
outcome in 33 SSc patients with primary organ involvement.
At baseline, patients had high mRss (median 30), a
moderately decreased DLCO (median 62%), mildly decreased
FVC (median 72%) and relatively early disease (median
duration 20.5 months). The mRss decreased to approximately
5 after 4 years (Figure 3). There was also a dramatic
Arthritis Research & Therapy    Vol 9 Suppl 2 Matucci-Cerinic et al.
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Figure 2
Cyclophosphamide versus placebo: effect on FVC. CYC,
cyclophosphamide; FVC, forced vital capacity. Reproduced with
permission from Tashkin et al. N Engl J Med 2006 Copyright © 2006
Massachusetts Medical Society [4].
improvement in HAQ to almost zero in terms of the group
mean. Visceral involvement stabilized [24]. Although this was
an open study and subject to all of the significant problems of
such trials, the apparent dramatic responses are encouraging
and indicate that the measurements we use at present may
be adequate for highly effective therapeutic options. A
multicentre, randomized, controlled, National Institutes of Health
approved trial of these approaches has started in the USA.
The European Group for Blood and Marrow Transplantation/
European League Against Rheumatism reported an analysis
of their database of 57 patients with SSc treated by
haematopoietic stem cell transplantation, with more than
6 months of follow up, in European phase I to II studies from
1996 to 2002 [25]. The analysis showed that response in
two-thirds of the patients after haematopoietic stem cell
transplantation was durable, with an acceptable transplant-
related mortality of 8.7%. Based on these findings, a
prospective, randomized trial is in progress in Europe.
Lessons from observational studies of
databases and registries
Although clinical trials are a valuable means of assessing new
treatments, in SSc the lack of a definitive clinical trial
template with appropriate end-points for measuring treatment
success in this disease makes interpretation and comparison
of findings difficult. The use of observational studies of
databases and registries may help to elucidate the clinical
course of this heterogeneic disease and assist in the identi-
fication of factors that may be employed to enrich the patient
population, and so increase the likelihood of demonstrating a
treatment effect with the available therapeutic options.
Limitations of clinical trials
Clinical trials are characterized by their ability to answer very
specific, straightforward questions in a well defined relatively
homogeneous patient population. Although this can provide
important answers, it may not be representative of complex
real-life scenarios. For example, the patient populations tend to
be highly selected, and long-term outcome studies are
notoriously difficult to perform and are often limited in duration
because of cost. A frequent problem encountered in rare
diseases such as SSc is the difficulty in obtaining adequate
patient numbers. As a result, compromises are made in terms
of study entry criteria and patient management, which can
complicate interpretation of the results. Another important
aspect to consider in trials of SSc is the extremely slow
progression of disease in many patients and the fact that
spontaneous improvement is observed in many. This makes it
difficult to show benefits of therapy over placebo. As a result,
meaningful results are more likely to be obtained by identifying
and targeting patients who are most likely to progress, rather
than those who remain stable over the course of a clinical trial.
The optimal way to achieve this is a matter of much debate.
In addition to these well controlled clinical trials, which are
ideal for testing hypotheses but are not representative of all
clinical situations, there are alternative ways to examine
clinical experience. These include descriptive or observational
studies, such as case reports, case series and collections of
patients or specimens. Databases and registries that aim to
gather data from large groups of patients can provide a
wealth of information. A more analytical approach is analysis
of cohorts and use of observational studies to generate
specific hypotheses, although such observational studies
cannot adequately test these hypotheses. These obser-
vational studies can be used to address a variety of features,
such as associations, risk factors and, to varying degrees,
organ outcomes and survival. Unfortunately, the effects of
therapy are inevitably confounded by the methodology unless
very large cohorts are used; for uncommon diseases (for
instance, SSc) such cohorts are not available in a fully
developed and highly enriched form, with the possibility of
long-term follow up.
Cohort studies do have significant strengths: they can be
used to study high-risk patients even before they develop
certain manifestations; several outcomes can be studied for
each exposure; and statistical modelling can be applied to
determine significance in-depth. There are of course limita-
tions to such studies as well: they are time consuming; their
management is challenging; missing data are a major
problem; and there are often problems resulting from loss to
follow up. Moreover, because they are not controlled, cohort
studies comprise populations that are inevitably subject to
Available online http://arthritis-research.com/content/9/S2/S7
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Figure 3
Pilot study showing mRss over time following immunoablation therapy.
mRss, Modified Rodnan Skin Score. This research was originally
published in Blood Online. Nash RA et al. High-dose
immunosuppressive therapy and autologous hematopoietic cell
transplantation for severe systemic sclerosis: long-term follow-up of the
U.S. multicenter pilot study. Blood. Prepublished online April 23,
2007; DOI 10.1182/blood-2007-02-072389 [24].
channelling bias, the effects of changing diagnostic criteria
and methodology, and the lack of concomitant comparison
populations. Despite these limitations, cohort studies can
provide valuable insights, and it may be possible to enrich
them to make them more meaningful, for example by including
rating scales and staging systems, and by using
sophisticated analytical methods to evaluate the entire clinical
course and outcome of the patient. They can generate solid
hypotheses and can serve as strong supporting, or indeed,
contradictory evidence for randomized, controlled trials. In
fact, observational studies and controlled trials should be
considered complementary methodologies, not competing
ones. Over recent years a broad base of clinical information
has been gained from sources other than clinical trials, and
there are a great number of observational studies, databases
and registries in many countries.
Findings from observational databases and patient
registries
Features of systemic sclerosis and its clinical course
Autoantibodies are associated with a number of clinical
features of SSc. The degree of pulmonary involvement in
patients with different autoantibodies varies considerably
(Table 1). It is likely that autoantibodies will play an important
role as far as subclassification of SSc and its response to
therapy are concerned. Interestingly, patients with anti-
polymerase III antibodies have minimal severe fibrosis; these
patients are likely to have very different outcomes to those of
patients with both PAH and PF [26].
Identification of different patterns among patients with early
diffuse systemic sclerosis
An analysis of skin scores of the Royal Free Scleroderma
Database (1985 to 2004) provided interesting insights into
the patterns of disease in patients with early diffuse SSc. At
the time of the analysis, the database included 1,742 patients
with the expected distribution of 33% with diffuse disease
and a 4:1 ratio of women to men. Of these patients, data
were available from 196 patients with early diffuse disease
(patients within 1 year of disease onset) for whom at least
3 years of follow-up data were available. In addition, 29
patients with early diffuse disease who died within 3 years
were identified. Latent trajectory modelling was used to
evaluate longitudinal data and so estimate and predict
unobserved underlying trajectories among these patients.
Three groups of patients were identified: a group of patients
with very stable severe disease; a group that had
intermediate disease that was initially fairly severe but then
improved; and a group that started out with fairly mild disease
and ended up very mild. These groupings of patients also
correlated with clinical manifestations and outcomes,
including major organ based complications and death. The
outcome that was most strongly associated with skin score
was death during follow up [27]. Such information could
prove useful for identifying patients with severe disease who
are most likely to benefit from treatment, and for stratifying
clinical trial populations to increase the likelihood of
observing a treatment effect.
The University of Pittsburgh Scleroderma Databank continues
to be a valuable source of data from SSc patients. The
database was initiated in 1979 and includes data from 2,500
patients, 28,000 patient visits, a mean total observation time
of 8 years, 22,000 patient-years of treatment, almost 10,000
skin scores, and 8,000 HAQ assessments. In an analysis of
time to development of severe disease in diffuse SSc, a large
group of more than 400 patients from the Pittsburgh
Scleroderma Databank was assessed over 10 years. Severe
Arthritis Research & Therapy    Vol 9 Suppl 2 Matucci-Cerinic et al.
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Table 1
Clinical features associated with systemic sclerosis autoantibodies
Antibodies
ACA Th/To U1RNP U3RNP Topo Pol III
Patient characteristics Female MCTD African American
Disease subtype Limited Limited Limited Diffuse Diffuse Diffuse
Joint/skin involvement ↓ Joint ↓ Joint ↑ Joint ↑↑ Skin
Muscle involvement ↑ ↑
Calcinosis ↑
Acroosteolysis ↑ ↑
DUs Yes Yes
PAH ± PF PAH PAH PAH PAH + PF PF ↓↓ PF
Renal crisis Yes Yes ↑
ACA, anticentromere antibodies; DU, digital ulcer; MCTD, mixed connective tissue disease; PAH, pulmonary arterial hypertension; PF, pulmonary
fibrosis; Pol III, polymerase III; Topo, topoisomerase; U1RNP, U1 ribonuclear protein; U3RNP, U3 ribonuclear protein.
disease was defined as renal crisis, heart disease (including
congestive heart failure, symptomatic arrhythmias, or severe
pericardial effusion) and severe PF (but not PAH) with an
FVC predicted below 55%. More than half of these patients
experienced organ damage within 4 years of the onset of the
very first symptom of SSc (Figure 4). Kidney damage
appeared to develop most rapidly, with the majority of
patients having developed renal crisis within the first 2 years
of SSc onset. However, in recent years, with the use of
angiotensin-converting enzyme inhibitors, the incidence of
death because of renal crisis has decreased significantly,
whereas the incidence of death due to PF has increased.
Lung disease as described above has a variable outcome.
Ten-year survival is closely associated with the FVC at the
time of first evaluation (Figure 5). In patients with an FVC
predicted of under 55%, PF is the cause of death or a major
contributing factor in almost three-quarters of patients [28]. In
this study, at the time of death patients had SSc symptoms
for 10 years but pulmonary symptoms for only 5 years. This
could suggest that onset of pulmonary disease occurs
relatively late in the disease course. However, when serial
pulmonary function tests were investigated in this group of
patients, most of the volume loss was found to occur during
the initial 4-year period when the patients were essentially
asymptomatic [28]. Typically, patients are not seen until they
are at 65% of FVC predicted, when little further deterioration
is necessary before severe problems develop.
A retrospective analysis was performed to determine whether
any of the therapies used in the management of SSc were of
potential benefit in patients with ILD [28]. Changes in mean
%FVC predicted and rate of change over the initial 2 years of
drug therapy were evaluated in patients with FVC predicted
under 70% (n = 122). Therapies included high-dose
prednisone and other immunosuppressive drugs (namely
methotrexate, chlorambucil, cyclophosphamide and D-
penicillamine). A group of patients who received no drug was
also evaluated. FVC was unchanged or reduced in all groups
apart from patients receiving cyclophosphamide over this first
2-year time period. The improvement in the
cyclophosphamide group was maintained over time, whereas
the other patients either stabilized or deteriorated. This
observational study was the one that led to the controlled
cyclophosphamide trial discussed above [4].
Pulmonary arterial hypertension in patients with
systemic sclerosis
PAH is a major complication of SSc, and once it develops
1-year survival is estimated to be 55% to 68%, as compared
with more than 90% in SSc patients without PAH [29,30]. As
such, it is important to be able to identify which SSc patients
are at greatest risk for developing PAH. A study that looked
at risk factors for PAH in SSc patients found that PAH
patients had disease of longer duration [31]. No differences
in FVC between SSc patients with PAH and those without
PAH at the time of diagnosis were identified. However, DLCO
was very low, and more than half of the patients had
developed new moderate pericardial effusions. In a case-
control study, examination of the DLCO 5 years before the
echocardiographic diagnosis of PAH in these patients
revealed that even at that time they had a lower mean value
compared with control individuals (52% versus 81%).
Available online http://arthritis-research.com/content/9/S2/S7
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Figure 4
Time to development of severe disease in patients with diffuse SSc.
SSc, systemic sclerosis.
Figure 5
Association between severity of PF and survival in patients with SSc.
FVC, forced vital capacity; PF, pulmonary fibrosis; SSc, systemic
sclerosis. Reproduced with permission from Steen et al. Arthritis
Rheum 1994 © John Wiley & Sons/American College of
Rheumatology [28].
Additionally, data from a smaller number of patients for whom
serial pulmonary function tests were available for up to
15 years before the diagnosis of PAH. These data
demonstrated that DLCO decreased over that time from 80%
predicted to 40% predicted by the time when PAH was
diagnosed, as compared with those who had not developed
PAH. In these patients, DLCO remained at approximately 80%
predicted.
In the same study, vascular manifestations were also examined
in SSc patients with and without PAH [31]. Although patients
with and those without PAH had similar frequencies of
Raynaud’s (about 96%) and digital gangrene (8% to 13%),
the severity of ulcers on the scleroderma HAQ (0 to 3 scale)
was significantly greater in the PAH cases than in control
individuals (0.75 versus 0.45; P < 0.01). In addition, at the
time of PAH diagnosis, a significantly greater proportion of
patients had also developed new DUs (38% versus 10%;
P < 0.05). Interestingly, there was significantly lower use of
calcium channel blockers in these patients (P < 0.001),
suggesting that these drugs might have had a preventative
effect on development of PAH.
PHAROS
Existing databases and registries have been able to deter-
mine factors in SSc patients that predispose to development
of PAH. However, not all patients with a low DLCO develop
PAH, and it is important to identify those patients who will
develop PAH and over what time period. This is one of the
objectives of the Pulmonary Hypertension Assessment
Registry of Scleroderma (PHAROS). Other objectives of the
registry are to identify the best risk factors for PAH and to
determine the outcomes of patients who develop PAH.
Patients included in the registry are either those deemed to
be at high risk for PAH (DLCO below 55% predicted,
FVC/DLCO above 1.6 and pulmonary artery systolic pressure
on echo above 35 mmHg) or patients with PAH confirmed by
right heart catheterization. The key outcome measures are
time to definite PAH in high-risk patients; in those with
definite PAH, the key outcome measures are change in
therapy, hospitalization for PAH, and death. Secondary
outcomes include 6MWD, pulmonary function testing and
dyspnoea questionnaires. It is anticipated that the registry will
provide some answers to many of the open questions that
remain in the arena of SSc-PAH, which will enable us to
initiate prevention trials in enriched populations of patients at
high risk for developing PAH and, ultimately, to improve
guidelines for therapy.
Conclusion
Advances have been made in the treatment of SSc but are
hampered by its complex nature and disease heterogeneity.
Most nonspecific antifibrotic compounds have exhibited few
clinical benefits, although more targeted therapies that address
SSc-specific abnormalities are showing some promise. For
example, the dual ET-1 receptor antagonist bosentan has
yielded positive results in prevention of DUs in SSc patients
as well as in the life-threatening complication of PAH in these
patients. Single endothelin receptor antagonists [32] and the
phosphodiesterase 5 inhibitor sildenafil [33] are also being
evaluated, although not specifically for their effect on DUs.
Results of trials in ILD have highlighted the need for a
definitive trial design template for studies in this patient
population, and it is becoming increasingly clear that, in a
disease such as SSc, the greatest chance of demonstrating a
disease-modifying effect is to target the pathogenesis of the
disease. Early and aggressive therapy, aimed at the immune
system and vasculature, may be best in the early stages of
the disease when vascular abnormalities and immunological
activity are greatest. Later, when fibrosis is more charac-
teristic and lipase progression slower, antifibrotic therapies -
not yet developed - may be more appropriate. Key challenges
for the future are to develop valid, sensitive, feasible
measurement tools and to identify risk factors that will allow
the enrichment of randomized, controlled clinical trial patient
populations so that clinically relevant treatment effects can be
observed.
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